Sanofi Pasteur Dengue Vaccine Promising But Questions Remain

(Reuters) - The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease.

The late-stage trial involved 10,275 healthy children aged 2-14 across five countries in Asia, a region that accounts for over two-thirds of the mosquito-borne disease's global burden.

Help employers find you! Check out all the jobs and post your resume.